Amanda Zatta1, Zoe Mcquilten1, Rangi Kandane-Rathnayake2, James Isbister3, Scott Dunkley4, John Mcneil1, Peter Cameron5, Louise Phillips6. 1. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 2. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia Australian Haemophilia Centre Directors' Organisation, Melbourne, Australia. 3. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia Transfusion Medicine, Royal North Shore Hospital, Sydney, Australia. 4. Haemophilia and Thrombosis Unit, Royal Prince Alfred Hospital, Sydney, Australia. 5. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia Emergency and Trauma Centre, Alfred Health, Melbourne, Australia. 6. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia Calembeena Consulting, Melbourne, Australia.
Abstract
BACKGROUND: Recombinant activated factor VII (rFVIIa) has been widely used as an off-licence pan-haemostatic agent in patients with critical bleeding. However, outside the trauma setting, there is relatively little high quality evidence on the risks and benefits of this agent. The Haemostasis Registry was established to investigate the extent of use, dosing, safety and outcomes of patients after off-licence rFVIIa treatment of critical bleeding. MATERIALS AND METHODS: The Registry recruited non-haemophiliac patients treated with rFVIIa from 2000-2009 (inclusive) in Australia and New Zealand. Detailed information was gathered on patients' demographics, context of bleeding, rFVIIa administration, laboratory results, blood component and other therapies, and outcomes. Outcome measures included subjectively assessed effect of rFVIIa on bleeding (response), adverse events (thromboembolic and other) and 28-day mortality. RESULTS: The registry included 3,446 cases in 3,322 patients (median [IQR] age 56 [33-70] years, 65% (n=2,147) male). Clinical indications included cardiac surgery (45%), other surgery (18%), trauma (13%), medical bleeding (6%), liver disease (6%), and obstetric haemorrhage (5%). The median [IQR] dose was 91 [72-103] μg/kg and 77% received a single dose. Reduction or cessation of bleeding was reported in 74% and 28-day survival was 71% but outcomes varied depending on clinical context. pH strongly correlated with outcome measures; 81% of patients with pH <7.1 died. Approximately 11% of patients had thromboembolic adverse events. In multivariate analysis, pH prior to administration and bleeding context were independently associated with reported response to rFVIIa and 28-day mortality. DISCUSSION: The Haemostasis Registry is the largest dataset of its kind and provides observational data on the off-licence use of rFVIIa over a 10-year period. It has been an invaluable resource for rigorously tracking adverse events and helping to inform clinical practice.
BACKGROUND: Recombinant activated factor VII (rFVIIa) has been widely used as an off-licence pan-haemostatic agent in patients with critical bleeding. However, outside the trauma setting, there is relatively little high quality evidence on the risks and benefits of this agent. The Haemostasis Registry was established to investigate the extent of use, dosing, safety and outcomes of patients after off-licence rFVIIa treatment of critical bleeding. MATERIALS AND METHODS: The Registry recruited non-haemophiliacpatients treated with rFVIIa from 2000-2009 (inclusive) in Australia and New Zealand. Detailed information was gathered on patients' demographics, context of bleeding, rFVIIa administration, laboratory results, blood component and other therapies, and outcomes. Outcome measures included subjectively assessed effect of rFVIIa on bleeding (response), adverse events (thromboembolic and other) and 28-day mortality. RESULTS: The registry included 3,446 cases in 3,322 patients (median [IQR] age 56 [33-70] years, 65% (n=2,147) male). Clinical indications included cardiac surgery (45%), other surgery (18%), trauma (13%), medical bleeding (6%), liver disease (6%), and obstetric haemorrhage (5%). The median [IQR] dose was 91 [72-103] μg/kg and 77% received a single dose. Reduction or cessation of bleeding was reported in 74% and 28-day survival was 71% but outcomes varied depending on clinical context. pH strongly correlated with outcome measures; 81% of patients with pH <7.1 died. Approximately 11% of patients had thromboembolic adverse events. In multivariate analysis, pH prior to administration and bleeding context were independently associated with reported response to rFVIIa and 28-day mortality. DISCUSSION: The Haemostasis Registry is the largest dataset of its kind and provides observational data on the off-licence use of rFVIIa over a 10-year period. It has been an invaluable resource for rigorously tracking adverse events and helping to inform clinical practice.
Authors: Oliver Flower; Louise E Phillips; Peter Cameron; Kerry Gunn; Scott Dunkley; Andrew Watts; Dorrilyn Rajbhandari Journal: Blood Coagul Fibrinolysis Date: 2010-04 Impact factor: 1.276
Authors: Carl J Hauser; Kenneth Boffard; Richard Dutton; Gordon R Bernard; Martin A Croce; John B Holcomb; Ari Leppaniemi; Michael Parr; Jean-Louis Vincent; Bartholomew J Tortella; Jeannett Dimsits; Bertil Bouillon Journal: J Trauma Date: 2010-09
Authors: Ian Roberts; Haleema Shakur; Adefemi Afolabi; Karim Brohi; Tim Coats; Yashbir Dewan; Satoshi Gando; Gordon Guyatt; B J Hunt; Carlos Morales; Pablo Perel; David Prieto-Merino; Tom Woolley Journal: Lancet Date: 2011-03-26 Impact factor: 79.321
Authors: Michael N Diringer; Brett E Skolnick; Stephan A Mayer; Thorsten Steiner; Stephen M Davis; Nikolai C Brun; Joseph P Broderick Journal: Stroke Date: 2009-12-03 Impact factor: 7.914
Authors: Louise E Phillips; Claire McLintock; Wendy Pollock; Stephen Gatt; Philip Popham; Gary Jankelowitz; Robert Ogle; Peter A Cameron Journal: Anesth Analg Date: 2009-12 Impact factor: 5.108
Authors: Rolf Rossaint; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund A M Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Donat R Spahn Journal: Crit Care Date: 2016-04-12 Impact factor: 9.097
Authors: J C Oldroyd; K M Venardos; N J Aoki; A J Zatta; Z K McQuilten; L E Phillips; N Andrianopoulos; D J Cooper; P A Cameron; J P Isbister; E M Wood Journal: BMC Res Notes Date: 2016-10-06
Authors: Edward Jegasothy; Jillian Patterson; Deborah Randall; Tanya A Nippita; Judy M Simpson; David O Irving; Jane B Ford Journal: BMC Med Res Methodol Date: 2018-11-16 Impact factor: 4.615
Authors: Joel T Feih; Janelle J Juul; Joseph R G Rinka; Lisa M Baumann Kreuziger; Paul S Pagel; Justin N Tawil Journal: Ann Card Anaesth Date: 2019 Oct-Dec